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receive financial support from industry performed better across our assessment 
criteria. We did not find substantial differences between NMAs published before 
January 1st, 2013, with studies published after that date. ConClusions: There 
is substantial variation in the NMA literature. Consensus among NMA guidelines 
is required to improve methodological quality, consistency, and transparency of 
study conduct and reporting.
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objeCtives: Propensity score matching (PSM) and Inverse Probability of Treatment 
Weighting (IPTW) are analytical methods used in comparative effective research 
(CER) to establish comparison groups. However, these methods may not be appli-
cable in studies with small sample sizes and unbalanced comparison groups. 
In such cases, where there is an unbalanced design due to unmeasured factors, 
difference-in-difference (DD) can be applied to estimate treatment effects. This 
research aims to apply DD to a small sample of multiple sclerosis (MS) patients with 
unbalanced comparison groups. Methods: A retrospective study was conducted 
using MarketScan Commercial Claims and Encounters and Medicare Supplemental 
and Coordination of Benefits Databases to compare MS patients who switched from 
glatiramer acetate (GA) to fingolimod (FTY) with another group maintaining con-
tinuous use of GA. IPTW and DD were applied to balance the comparison groups; 
PSM could not be implemented due to imbalance between groups. Using DD, the 
treatment effect (i.e. % of patients with relapse) was measured in the 1-year baseline 
period and the 1-year follow-up period as: (difference in relapses in the GA--> FTY 
group) minus (difference in relapses in the GA-only group). Results: IPTW was first 
employed to balance the two groups (GA--> FTY [n= 363]; GA-only [6,416]). Despite 
implementation of IPTW, the comparison groups could not be balanced on multiple 
factors such as patient demographics and clinical characteristics; therefore, DD was 
utilized. In the DD analysis, the % of patients with relapse in the GA--> FTY group 
in the baseline and follow-up periods were 30% and 13.8%, respectively (D= 16.2%); 
in the GA-only group, the % of patients with relapse in the baseline and follow-up 
periods were 14% and 11.5%, respectively (D= 2.5%). The estimated reduction of MS 
relapse rate from FTY was 13.7% (DD= 16.2%-2.5%). ConClusions: DD is an effec-
tive methodology which allows for estimating treatment effects from populations 
with unbalanced comparison groups.
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objeCtives: It is estimated that up to 400,000 persons in Mexico are hospital-
ized yearly for deep-vein thrombosis (DVT). DVT is the presence of a blood clot 
(thrombus) in the deep veins of the body. The main objective was to indirectly 
compare the use of tinzaparin, nadroparin and enoxaparin in terms of safety and 
efficacy for the treatment of deep-vein thrombosis using a network meta-analysis 
(NMA). Methods: To identify suitable studies for a systematic review of treat-
ment of DVT (submitted for abstract), the following databases were searched: 
MEDLINE, Pubmed, EMBASE, CENTRAL (all via The Cochrane Library), Imbiomed, 
HTA, for relevant studies recorded between April 1994 to April 2014. Only ran-
domised controlled trials assessing patients with DVT were included. Studies 
had to report the proportion of patients having recurrence of DVT (efficacy) and 
the proportion of patients having major bleeding (safety). Titles and abstracts 
were screened, data were extracted and risk of bias assessment was undertaken. 
. Bayesian NMA was used to compare the different interventions. Results: Four 
studies, assessing four low molecular weight heparins (LMWH), were judged to be 
sufficiently comparable for inclusion in the NMA. For the proportion of patients 
having recurrence of DVT or major bleeding, enoxaparin 1 mg/kg twice daily, tin-
zaparin 175 IU/kg once daily and nadroparin 100 IU/kg twice daily had a higher 
probability of being more effective and safe than unfractioned heparin. None of 
the LMWHs demonstrated a signiﬁcant superiority over each other in terms of 
efficacy and safety; therefore, the group of LMWHs is suitable for a further cost 
minimization analysis and reference price implementation. ConClusions: We 
found no evidence of differences between tinzaparin, nadroparin and enoxaparin 
for recurrence of DVT and major bleeding. Tinzaparin may be preferred by clini-
cians because it is always given once daily.
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objeCtives: The use of indirect comparisons (IC) is now an integral part of the 
Health Technology Assessment (HTA). When new interventions are assessed, 
Individual patient data (IPD), if available, can be used for comparison with pub-
lished aggregated (AGR) data. Methods exist to assess heterogeneity and incon-
sistency of IC; however in the absence of sufficient studies, IC may be required 
where differences may exist between inclusion/exclusion criteria, definition of 
outcomes and patient characteristics. Signorovitch (2010) has proposed the use 
of MAIC when IPD is available and provided various methods for matching the 
IPD to the AGR study. Methods: Through simulations we assessed different 
approaches to weight calculations, including weighting as originally proposed 
translated into 17 Asiatic languages (Chinese for China, Hong Kong, Singapore 
and Taiwan, Korean, Bengali, Gujarati, Hindi, Kannada, Malayalam, Marathi, 
Punjabi, Telugu, Urdu, Tamil for India and Singapore, and Malay for Singapore). 
The objective of this study was to identify the main translation challenges, and 
which items needed the most references to conceptual definitions. Methods: In 
each country, the linguistic validation was conducted with the author of the IBS-
QOL, using either the standard forward/backward methodology or the adjusted 
process with reviews by the author, a clinician, and cognitive interviews with 12 
patients. The basis for discussion was the list of concepts (LOC) elaborated with 
the author. For each country, the history grid of the translation process was ana-
lyzed. References/reminders of the LOC and author’s interventions were counted for 
each item across countries. Results: Eleven items were found challenging (items 
2,3,4,7,9,16,18,25,28,31,32). Four of them needed the most to refer to the LOC, i.e., 
item 3 “I am bothered by how much time I spend on the toilet” (100% of the coun-
tries); item 18 “I feel I get less done…” (53%); item 25 “I feel sluggish…” (76%); and 
item 31 “I worry about losing control of my bowels” (59%). For instance, the main 
difficulties with item 3 were conceptual (“on the toilet” not to be confused with “in 
the toilet”), and cultural (e.g., lack of toilets in India, or people squatting, not sitting). 
Examples of challenges will be provided. ConClusions: The development of the 
LOC with the author proved to be critical to the translation process and enabled the 
conceptual harmonization of the translations.
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objeCtives: Matching-adjusted indirect comparison (MAIC) has been proposed as 
a new tool when conducting indirect treatment comparisons in the situation where 
individual-level data are available from one study, but only summary data are avail-
able from another study. This study evaluated the performance of the MAIC method 
proposed by Malangone and Sherman (2011) which is implemented by a resampling 
(bootstrapping) technique. Methods: Two patient-level data sets, similar to two 
clinical trials, were generated: the first with treatments A and placebo, and the 
second with treatments B and placebo. Other variables included in both data sets 
were survival time, censoring indicator, and two baseline categorical variables. In 
both data sets, interactions between baseline characteristics and treatments were 
incorporated such that differential treatment effects across baseline strata were 
present. The SAS programs illustrated in Malangone and Sherman were adopted for 
the MAIC analysis. First, MAIC was applied to a situation in which only summary 
data were available from the first data set and individual-level data were available 
from the second data set. Subsequently, the roles of two data sets were switched 
and the MAIC analysis was applied once again. Results: Using MAIC, when the 
first data set provided summary statistics, the hazard ratio (HR) (95% confidence 
interval [CI]) for A versus placebo was 0.283 (0.246-0.325); the HR (95% CI) for B ver-
sus placebo was 0.586 (0.466, 0.740). When the second data set provided summary 
data, the HR (95% CI) for A versus placebo was 0.489 (0.390-0.612) and for B versus 
placebo was 0.237 (0.205-0.273). The two comparisons produced opposite significant 
inferences. ConClusions: The method proposed by Malangone and Sherman is 
an interesting addition to the MAIC field, but results could be misleading under 
some circumstances. Therefore, the conditions under which this method is suitable 
should be explored further.
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objeCtives: To evaluate the methodological quality of published network meta-
analyses (NMA). Methods: We performed a systematic review of the NMA lit-
erature (through July 2014). For NMAs including pharmaceuticals we assessed 
general study characteristics, study reproducibility and transparency, methods, 
and reporting of findings. We compared NMAs published in higher impact factor 
journals with those published in lower impact factor journals, NMAs published 
before January 1st, 2013, with those published after that date, and studies receiv-
ing financial support from industry with those receiving financial support from 
non-profit institutions or that did not receive support. Results: The systematic 
literature search identified 318 NMAs meeting our inclusion criteria. Forty-eight 
percent of NMAs were published after January 1st 2013, and the majority received 
financial support from non-profit institutions or did not receive support (68%). 
We found notable inconsistencies among NMAs. Eighty percent reported search 
terms, 65% presented sufficient data to reproduce the analysis, 90% the study 
characteristics of included clinical trials, and 61% the network diagram. Seventy 
percent reported a risk of bias assessment of included clinical trials, 56% a sensi-
tivity analysis, and 40% an assessment of model fit. Among NMAs with a closed 
loop, 69% assessed the consistency of direct and indirect evidence. Sixty-four 
percent of NMAs presented the complete matrix of head-to-head treatment com-
parisons. For Bayesian NMAs, 41% reported the probability of each treatment being 
best, 31% reported efficacy ranking, and 16% reported or referenced the model 
code. NMAs published in higher impact factors journals and those that did not 
